Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

被引：0
|
作者：
Deborah JL Wong
Lidia Robert
Mohammad S Atefi
Amanda Lassen
Geetha Avarappatt
Michael Cerniglia
Earl Avramis
Jennifer Tsoi
David Foulad
Thomas G Graeber
Begonya Comin-Anduix
Ahmed Samatar
Roger S Lo
Antoni Ribas
机构：
[1] University of California Los Angeles (UCLA),Department of Medicine, Division of Hematology
[2] UCLA,Oncology
[3] UCLA,Department of Molecular and Medical Pharmacology
[4] Jonsson Comprehensive Cancer Center at UCLA,Department of Surgery, Division of Surgical
[5] Discovery Oncology Merck Research Laboratories,Oncology
[6] Merck Research Laboratories,Department of Medicine, Division of Dermatology
[7] UCLA,undefined
[8] University of Applied Sciences,undefined
[9] Universitat Autonoma de Barcelona,undefined
[10] UAB,undefined
来源：
Molecular Cancer | / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Deborah JL Wong
    Lidia Robert
    Mohammad S Atefi
    Amanda Lassen
    Geetha Avarappatt
    Michael Cerniglia
    Earl Avramis
    Jennifer Tsoi
    David Foulad
    Thomas G Graeber
    Begonya Comin-Anduix
    Ahmed Samatar
    Roger S Lo
    Antoni Ribas
    Molecular Cancer, 13
  • [2] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Wong, Deborah J. L.
    Robert, Lidia
    Atefi, Mohammad S.
    Lassen, Amanda
    Avarappatt, Geetha
    Cerniglia, Michael
    Avramis, Earl
    Tsoi, Jennifer
    Foulad, David
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Samatar, Ahmed
    Lo, Roger S.
    Ribas, Antoni
    MOLECULAR CANCER, 2014, 13
  • [3] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma (vol 13, 194, 2014)
    Wong, Deborah J. L.
    Robert, Lidia
    Atefi, Mohammad S.
    Lassen, Amanda
    Avarappatt, Geetha
    Cerniglia, Michael
    Avramis, Earl
    Tsoi, Jennifer
    Foulad, David
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Samatar, Ahmed
    Lo, Roger S.
    Ribas, Antoni
    MOLECULAR CANCER, 2015, 14
  • [4] Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
    Sabbatino, Francesco
    Wang, Yangyang
    Scognamiglio, Giosue
    Favoino, Elvira
    Feldman, Steven A.
    Villani, Vincenzo
    Flaherty, Keith T.
    Nota, Sjoerd
    Giannarelli, Diana
    Simeone, Ester
    Anniciello, Anna M.
    Palmieri, Giuseppe
    Pepe, Stefano
    Botti, Gerardo
    Ascierto, Paolo A.
    Ferrone, Cristina R.
    Ferrone, Soldano
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (07):
  • [5] The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models
    Haendler, Bernard
    Gelato, Kathy A.
    Schockel, Laura
    Sugawara, Tatsuo
    Lejeune, Pascale
    Ellinger-Ziegelbauer, Heidrun
    Fernandez-Montalvan, Amaury E.
    Holton, Simon
    Siegel, Stephan
    Heroult, Melanie
    Walter, Annette
    Ince, Stuart
    Ocker, Matthias
    CANCER RESEARCH, 2016, 76
  • [6] Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
    Sullivan, Ryan J.
    Janku, Filip
    Li, Bob T.
    Wong, Deborah
    Sosman, Jeffrey
    Keedy, Vicki
    Buchbinder, Elizabeth
    Tolcher, Anthony
    Varghese, Anna
    Hyman, David M.
    Flaherty, Keith T.
    Ribas, Antoni
    Carvajal, Richard
    Wang-Gillam, Andrea
    Kluger, Harriet
    Patel, Manish
    Langecker, Peter
    Varterasian, Mary
    Welsch, Dean
    Infante, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [7] Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma
    Fedorenko, Inna V.
    Fang, Bin
    Koomen, John M.
    Gibney, Geoffrey T.
    Smalley, Keiran S. M.
    MELANOMA RESEARCH, 2014, 24 (05) : 448 - 453
  • [8] Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
    Sinik, Lenka
    Minson, Katherine A.
    Tentler, John J.
    Carrico, Jacqueline
    Bagby, Stacey M.
    Robinson, William A.
    Kami, Rotem
    Burstyn-Cohen, Tal
    Eckhardt, S. Gail
    Wang, Xiaodong
    Frye, Stephen, V
    Earp, H. Shelton
    DeRyckere, Deborah
    Graham, Douglas K.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 278 - 288
  • [9] ERK activity in mutant BRAF melanoma - A live report
    Aplin, Andrew E.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [10] Potent anticancer activity against both BRAF-mutant and BRAF wild-type melanoma cell lines using a novel CRM1 nuclear export inhibitor
    Fragomeni, Roberto A. Salas
    Chung, Hye-Won
    Shacham, Sharon
    Kauffman, Michael
    Cusack, James C.
    CANCER RESEARCH, 2012, 72
12345